Jacobs & Co. CA Has $7.26 Million Holdings in Amgen, Inc. (NASDAQ:AMGN)

Jacobs & Co. CA raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.6% in the second quarter, according to its most recent filing with the SEC. The firm owned 39,419 shares of the medical research company’s stock after purchasing an additional 234 shares during the quarter. Jacobs & Co. CA’s holdings in Amgen were worth $7,264,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in AMGN. Norges Bank bought a new position in shares of Amgen during the 4th quarter worth approximately $1,283,248,000. Thoroughbred Financial Services LLC lifted its holdings in shares of Amgen by 19,447.3% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock worth $180,539,000 after purchasing an additional 1,796,156 shares in the last quarter. Ellis Investment Partners LLC lifted its holdings in shares of Amgen by 18,906.7% in the 1st quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock worth $605,000 after purchasing an additional 602,746 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Amgen by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. Finally, First Trust Advisors LP lifted its holdings in shares of Amgen by 37.3% in the 2nd quarter. First Trust Advisors LP now owns 1,196,708 shares of the medical research company’s stock worth $220,529,000 after purchasing an additional 325,404 shares in the last quarter. 78.96% of the stock is owned by institutional investors and hedge funds.

In other news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the completion of the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total value of $351,360.00. Following the sale, the director now directly owns 16,219 shares of the company’s stock, valued at $2,849,353.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,425 shares of company stock valued at $804,312. Insiders own 0.25% of the company’s stock.



AMGN has been the topic of a number of recent research reports. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Co increased their target price on Amgen from $197.00 to $202.00 and gave the stock a “market perform” rating in a report on Monday. Credit Suisse Group initiated coverage on Amgen in a report on Monday, May 20th. They issued an “outperform” rating and a $208.00 target price on the stock. BMO Capital Markets set a $230.00 target price on Amgen and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, Royal Bank of Canada reiterated a “hold” rating on shares of Amgen in a report on Sunday. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $211.78.

NASDAQ AMGN traded down $4.42 on Wednesday, reaching $201.70. The company had a trading volume of 782,296 shares, compared to its average volume of 3,052,886. The stock has a market capitalization of $117.69 billion, a PE ratio of 14.01, a P/E/G ratio of 2.30 and a beta of 1.19. The business has a fifty day moving average price of $182.89. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $211.90. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the firm posted $3.83 EPS. Amgen’s quarterly revenue was down 3.1% compared to the same quarter last year. Sell-side analysts predict that Amgen, Inc. will post 14.23 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.88%. The ex-dividend date of this dividend is Wednesday, August 14th. Amgen’s dividend payout ratio is presently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: What is dollar cost averaging (DCA)?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.